Leveraging artificial intelligence and machine learning in kinase inhibitor development: advances, challenges, and...

Area of Science:

• Biochemistry and Pharmacology
• Computational Biology and Bioinformatics
• Drug Discovery and Development

Background:

• Protein kinases are crucial cell signaling regulators implicated in cancer and autoimmune diseases.
• Kinase inhibitors like imatinib demonstrate therapeutic value, but challenges persist in developing selective and potent drugs.
• The conserved ATP-binding site, off-target effects, resistance, and patient variability complicate kinase inhibitor development.

Purpose of the Study:

• To review the transformative applications of AI and ML in designing, optimizing, and repurposing kinase inhibitors.
• To explore how AI/ML methods address key obstacles in kinase-targeted drug discovery.
• To highlight the potential of AI/ML in accelerating the development of novel kinase inhibitors.

Main Methods:

• Review of AI/ML methodologies including deep learning, graph neural networks, and generative models.
• Analysis of AI/ML applications across the drug discovery pipeline: target identification, virtual screening, SAR modeling, resistance prediction, and clinical trial design.
• Examination of case studies showcasing AI-optimized kinase inhibitors (e.g., BTK, EGFR).

Main Results:

• AI/ML methods offer solutions for challenges such as target identification, virtual screening, and predicting drug resistance.
• Case studies demonstrate the real-world impact of AI in optimizing kinase inhibitors.
• Current limitations include data sparsity, model interpretability, and the gap between computational and experimental findings.

Conclusions:

• AI/ML integration with medicinal chemistry promises to accelerate and refine kinase inhibitor development.
• Emerging directions include federated learning, personalized kinase inhibitors, and AI-enabled combination therapies.
• AI/ML holds significant potential for advancing the next generation of kinase-targeted therapeutics.